Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846671 · ClinicalTrials.gov registry record · Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
A Phase 3 study of Chronic Lymphocytic Leukemia and CLL, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06846671 is a Phase 3 study of Chronic Lymphocytic Leukemia and CLL that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 250 participants, above the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT06846671, a Phase 3 study of Chronic Lymphocytic Leukemia and CLL, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG BGB-16673
- DRUG Rituximab
- DRUG Bendamustine
- DRUG Idelalisib
Study Locations (20)
Florida
- Florida Oncology and Hematology - Fort Myers
- Baptist Md Anderson Cancer Center - Jacksonville
- Cleveland Clinic Florida - Weston
California
- UCLA Department of Medicine Hematologyoncology - Los Angeles
- Pih Health Whittier Hospital - Whittier
New York
- Memorial Sloan Kettering Cancer Center Mskcc - New York
- Clinical Research Alliance, Inc - Westbury
Ohio
- University Hospitals - Cleveland
- Dayton Physician Network - Dayton
Pennsylvania
- West Penn Hospital - Pittsburgh
- Cancer Care Associates of York - York
Arkansas
- St Bernards Medical Center - Jonesboro
Colorado
- Rocky Mountain Cancer Centers (Williams) Usor - Aurora
Georgia
- Emory University Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-04-10 |
| Est. Completion | 2030-02-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06846671
The ClinicalTrials.gov registry entry for NCT06846671 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (38% higher). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax is the first listed.
NCT06846671 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT06846671 about?
NCT06846671 is a clinical study titled "A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors". The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small l...
What is the current status of trial NCT06846671?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2025-04-10. Estimated completion is 2030-02-14.
What conditions does trial NCT06846671 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, CLL.
What interventions are being tested in trial NCT06846671?
The interventions under investigation include: Venetoclax (DRUG), BGB-16673 (DRUG), Rituximab (DRUG), Bendamustine (DRUG), Idelalisib (DRUG).
Who is sponsoring clinical trial NCT06846671?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846671 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RECRUITING · Phase 3
-
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 3
-
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RECRUITING · Phase 3
-
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.